|
|
|
| Study on Route Selection of Systematization of Drug Patent Linkage in China |
| Xie Wei1,2, Ma Zhiguo1, Zhang Lei1 |
1. School of Law, Xi'an Jiaotong University, Xi'an 710049, China;
2. College of Medicine and Phamacy, Shaanxi Institute of International Trade and Commerce, Xi'an 712046, China |
|
|
|
|
Abstract The accessibility of medicines is a basic evaluation indicator of public health and well-being.Availability and affordability separate the two ends of drug accessibility.Balancing the interests of the two ends of drug accessibility dynamically is regarded as the criterion of drug patent linkage system.To a certain extent, the previous revisions of Patent Law of China have promoted the process of drug patent linkage, and the relevant policies and regulations in the field of drugs are also exploring the possibility of drug patent linkage gradually.Through the comparative analysis of the mode of drug patent association outside the region, it is found that compared with the mode of independent operation of drug patent, the mode of drug patent linkage system is more conducive to promoting the development of innovative drug industry.However, China's drug patent linkage has not reached the level of systematization at present, and there are a series of difficulties.Therefore, we should construct a drug patent linkage system with Chinese characteristics from the aspects of relevant legislation, registration and publicity, linkage mechanism, decision mechanism and duration of rights.
|
|
Received: 04 September 2020
|
|
|
|
|
|
[1]李想.医药专利链接制度运行机理研究[J].电子知识产权,2019 (3):13-21.
[2]马碧玉,康云海.中印医药产业专利制度的比较分析[J].东南亚南亚研究,2017 (2):64-69.
[3]黄金荣. “规范性文件”的法律界定及其效力[J].法学,2014 (7):10-20.
[4]刘立春,朱雪忠.美国和加拿大药品专利链接体系要素的选择及其对中国的启示[J].中国科技论坛,2014 (1):147-154.
[5]European Commission.Pharmaceuticals:commission calls on Italy to comply with EU rules on marketing authorization of generic drugs[EB/OL]. (2012-01-26)[2020-07-13].http://europa.eu/rapid/press-release_IP-12-48_en.htm.
[6]邱福恩.美国药品专利链接制度实践情况及其启示[J].知识产权,2018 (12):87-93.
[7]丁锦希,韩蓓蓓.中美药品专利链接制度比较研究[J].中国医药工业杂志,2008 (12):950-955.
[8]陈敬,史录文.美国药品专利链接制度研究[J].中国新药杂志,2012 (22):2591-2594+2599.
[9]肖建玉,沈爱玲.加拿大药品专利链接制度对中国的启示[J].中国卫生事业管理,2010 (10):677-679.
[10]朱力宇.法理学原理与案例教程[M].北京:中国人民大学出版社,2007.
[11]饶兰兰,谈江萍.别居制度:价值分析与法律思考[J].江西社会科学,2009 (8):192-196.
[12]苏冬冬.药品专利链接制度的正当性及制度价值分析[J].电子知识产权,2019 (3):4-12. |
|
|
|
2021, Vol. 2 
